Commission Implementing Decision (EU) 2017/1445 of 8 August 2017 on the group of products whose principal intended action, depending on proanthocyanidins (PAC) present in cranberry (Vaccinium macrocarpon), is to prevent or treat cystitis
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
Adopted EU legal act considered by the EU and the EEA EFTA States not to be relevant for incorporation into the EEA Agreement Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XXX Medical Devices
Legal documents
Commission Implementing Decision (EU) 2017/1445 of 8 August 2017 on the group of products whose principal intended action, depending on proanthocyanidins (PAC) present in cranberry (Vaccinium macrocarpon), is to prevent or treat cystitis
Durchführungsbeschluss (EU) 2017/1445 der Kommission vom 8. August 2017 über die Produktgruppe, deren bestimmungsgemäße Hauptwirkung, die auf Proanthocyanidinen (PAC) aus Cranberries (Vaccinium macrocarpon) beruht, die Prävention und Behandlung von Zystitis ist (Bekannt gegeben unter Aktenzeichen
History
08.08.2017
Adoption date in the EU
30.08.2017
Compliance date in the EU
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.